



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kenneth. Brasel et al. Docket No.: 2836-A  
Serial No.: 08/ 725,540 Art Unit: 1816  
Filed: October 3, 1996 Examiner: E. Rabin  
For: DENDRITIC CELL STIMULATORY FACTOR

**ELECTION OF INVENTION**

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:

In response to the Office Action date June 26, 1997 in connection with the above  
referenced application, please consider the following election of invention.

**The Restriction of Claims**

The United States Patent and Trademark Office ("USPTO") believes that there exist nine  
separately patentable inventions within the 19 claims as originally filed. The USPTO has stated  
that the Groups of invention are as follows:

Group I, claims 1-5, drawn to a method of enhancing an immune response to treat  
infectious disease.

Group II, claims 1, 2, 6 and 7, drawn to a method of enhancing an immune response to  
treat cancer.

Group III, claims 1 and 18, drawn to a method of inducing tolerance.

Group IV, claims 8-11, drawn to a population of antigen-pulsed dendritic cells.

Group V, claims 12-14, drawn to a method of differentiating hematopoietic cells.

Group VI, claim 15, drawn to a method of preparing antigen-specific T cells.

Group VII, claim 16, drawn to a method of enhancing vaccination.

Group VIII, claim 17, drawn to a vaccine adjuvant.

Group IX, claim 19, drawn to cell expansion media.

First, the USPTO alleges that Groups IV and VI are related as product and process of  
use. Instead of explaining how they are so related, the USPTO simply reiterates a portion of  
MPEP §806.05(h). The USPTO also stated that Groups VIII and VII are related as product  
and process of use, again only citing the MPEP without further explanation. Further, the

#6  
elec  
RECEIVED  
97 DEC 10 PM 4:47  
GROUP 180